📊 CGTX Key Takeaways
Is Cognition Therapeutics Inc. (CGTX) a Good Investment?
Cognition Therapeutics is a pre-revenue biotech company with minimal revenue (-$10K) and substantial operating losses (-$34.1M), indicating it is in early-stage clinical development with no commercialized products. While the company maintains strong liquidity with $39.3M in cash and a 6.44x current ratio, ongoing negative cash flows of -$21.2M annually suggest the cash runway is limited to approximately 1.8 years at current burn rates, creating significant execution and dilution risk.
Cognition Therapeutics has a clean balance sheet with substantial cash, minimal liabilities, and no meaningful debt, which supports near-term operating flexibility. However, the company remains essentially pre-revenue and deeply unprofitable, with negative operating cash flow and losses that are large relative to its equity base, so the fundamental story depends more on future clinical and commercialization execution than current business performance. The core fundamental profile is financially solvent but operationally weak, which supports a cautious stance.
Why Buy Cognition Therapeutics Inc. Stock? CGTX Key Strengths
- Strong liquidity position with $39.3M cash and 6.44x current ratio providing operational flexibility
- No meaningful debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk
- Stockholders equity of $36.5M provides reasonable balance sheet cushion relative to asset base
- Strong liquidity with $39.33M in cash and 6.44x current and quick ratios
- Very low leverage with no meaningful long-term debt and only $6.87M in total liabilities
- Low capital expenditure needs, preserving cash for R&D and operations
CGTX Stock Risks: Cognition Therapeutics Inc. Investment Risks
- Negative operating cash flow of -$21.2M annually with minimal revenue indicates company is pre-commercial with uncertain pathway to profitability
- Limited cash runway of approximately 1.8 years at current burn rate creates near-term financing risk and potential shareholder dilution
- High insider activity (9 Form 4 filings in 90 days) warrants monitoring for potential value destruction or significant corporate events
- Business is effectively pre-revenue, making growth quality and operating leverage very weak
- Large operating and net losses are driving negative ROE, negative ROA, and ongoing cash burn
- Cash runway could compress if operating cash outflows remain near current levels without meaningful revenue inflection
Key Metrics to Watch
- Cash burn rate trend and runway extension milestones
- Clinical trial progress and regulatory pathway developments
- Revenue recognition timing and commercialization success of lead programs
- Quarterly operating cash burn relative to cash balance
- Revenue progression and reduction in operating loss as pipeline programs advance
Cognition Therapeutics Inc. (CGTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 211,550.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 6.44x current ratio provides a solid financial cushion.
CGTX Profit Margin, ROE & Profitability Analysis
CGTX vs Healthcare Sector: How Cognition Therapeutics Inc. Compares
How Cognition Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cognition Therapeutics Inc. Stock Overvalued? CGTX Valuation Analysis 2026
Based on fundamental analysis, Cognition Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cognition Therapeutics Inc. Balance Sheet: CGTX Debt, Cash & Liquidity
CGTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cognition Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.86 indicates the company is currently unprofitable.
CGTX Revenue Growth, EPS Growth & YoY Performance
Cognition Therapeutics Inc. Dividends, Buybacks & Capital Allocation
CGTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cognition Therapeutics Inc. (CIK: 0001455365)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CGTX
What is the AI rating for CGTX?
Cognition Therapeutics Inc. (CGTX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CGTX's key strengths?
Claude: Strong liquidity position with $39.3M cash and 6.44x current ratio providing operational flexibility. No meaningful debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk. ChatGPT: Strong liquidity with $39.33M in cash and 6.44x current and quick ratios. Very low leverage with no meaningful long-term debt and only $6.87M in total liabilities.
What are the risks of investing in CGTX?
Claude: Negative operating cash flow of -$21.2M annually with minimal revenue indicates company is pre-commercial with uncertain pathway to profitability. Limited cash runway of approximately 1.8 years at current burn rate creates near-term financing risk and potential shareholder dilution. ChatGPT: Business is effectively pre-revenue, making growth quality and operating leverage very weak. Large operating and net losses are driving negative ROE, negative ROA, and ongoing cash burn.
What is CGTX's revenue and growth?
Cognition Therapeutics Inc. reported revenue of $-10.0K.
Does CGTX pay dividends?
Cognition Therapeutics Inc. does not currently pay dividends.
Where can I find CGTX SEC filings?
Official SEC filings for Cognition Therapeutics Inc. (CIK: 0001455365) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CGTX's EPS?
Cognition Therapeutics Inc. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CGTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cognition Therapeutics Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CGTX stock overvalued or undervalued?
Valuation metrics for CGTX: ROE of -55.1% (sector avg: 15%), net margin of 201,440.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CGTX stock in 2026?
Our dual AI analysis gives Cognition Therapeutics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CGTX's free cash flow?
Cognition Therapeutics Inc.'s operating cash flow is $-21.2M, with capital expenditures of $4.0K. FCF margin is 211,550.0%.
How does CGTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 201,440.0% (avg: 12%), ROE -55.1% (avg: 15%), current ratio 6.44 (avg: 2).